SpectraCure AB (publ) OMXSTO:SPEC:
RESULT AFTER TAX -35,006 TSEK IN Q3 2025
Spectracure Q3 Net Loss SEK 35 Mln
Earlier from Spectracure Ab
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Gets Approval To Commence Clinical Trial